Ad26/蛋白preF呼吸道合胞病毒疫苗在18至59岁伴有或不伴有重症呼吸道合胞病毒病高危合并症成人中的安全性与免疫原性:一项3期、随机、对照、免疫桥接试验
这项3期随机双盲安慰剂对照免疫桥接试验纳入1118名成人,比较18至59岁无(队列1,387人)或有(队列2,388人)慢性心肺合并症者与65岁及以上成人(队列3,343人)接种Ad26/蛋白preF RSV疫苗后的安全性和免疫原性。结果显示18至59岁成人(包括高危者)的RSV中和抗体滴度非劣于65岁及以上成人,接种后第15天pre-F A IgG抗体和RSV-F特异性干扰素-γ T细胞频率升高并至少维持6个月高于基线,反应原性可接受但呈年龄依赖性,18至59岁成人3级全身不良事件率高于65岁及以上成人。
要点
- 18至59岁成人(含高危者)接种后RSV中和抗体滴度非劣于65岁及以上成人。
- 接种后第15天pre-F A IgG抗体和RSV-F特异性干扰素-γ T细胞频率升高,至少维持6个月高于基线。
- 反应原性可接受但呈年龄依赖性,18至59岁成人3级全身不良事件率高于65岁及以上成人。
核心结论
- Ad26/蛋白preF RSV疫苗在伴有或不伴有慢性心肺合并症的18至59岁成人中诱导了稳健的体液和细胞免疫应答,幅度与65岁及以上成人相似,可据此推断该人群对RSV相关呼吸道疾病的效力和保护。
研究设计与样本
- 3期随机双盲安慰剂对照免疫桥接试验,纳入1118名成人,分为18至59岁无慢性心肺合并症组(队列1,387人)、18至59岁有慢性心肺合并症组(队列2,388人)和65岁及以上成人组(队列3,343人)。
- 在基线、第15天和第183天评估体液和细胞免疫应答,所有参与者均评估反应原性和安全性。
- 临床试验注册号NCT05070546。
主要发现
- 与65岁及以上成人相比,18至59岁成人(包括高危者)的RSV中和抗体滴度非劣。
- 接种后第15天pre-F A IgG抗体水平和RSV-F特异性干扰素-γ T细胞频率升高,所有队列至少6个月维持高于基线。
- 反应原性和安全性临床可接受但呈年龄依赖性,18至59岁成人3级全身不良事件率高于65岁及以上成人。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Respiratory syncytial virus (RSV) causes a significant disease burden in adults with chronic comorbidities. Rates of severe RSV disease and death are as high, or higher in younger adults with risk factors than in healthy older adults in whom RSV vaccination is recommended. We conducted an immunobridging study using the Ad26/protein RSV preF vaccine, which previously demonstrated efficacy in adults aged ≥65 years to support extrapolation of efficacy demonstrated in an older population to younger adult populations at high risk of severe RSV disease. METHODS: This Phase 3 randomized, double-blind, placebo-controlled trial assessed the safety/tolerability and immunogenicity of Ad26/protein preF RSV in adults aged 18-59 years without (Cohort 1) and with (Cohort 2) chronic cardiac or pulmonary comorbidities, compared to adults aged ≥65 years (Cohort 3) in whom efficacy against RSV disease was demonstrated. Humoral and cellular immune responses were assessed at baseline, Days 15 and 183. Reactogenicity and safety were assessed in all participants. RESULTS: 1118 participants were enrolled (Cohort 1: 387; Cohort 2: 388; Cohort 3: 343). Compared to adults aged ≥65 years RSV neutralizing antibody titers were non-inferior in adults aged 18-59 years, including those at high risk. Levels of pre-F A IgG antibodies and frequencies of RSV-F specific interferon-gamma T-cells increased by Day 15 post-vaccination, and remained above baseline for at least 6 months in all cohorts. Reactogenicity and safety were clinically acceptable but age-dependent, with higher rates of Grade 3 systemic adverse events in adults aged 18-59-years than adults ≥65 years. CONCLUSION: Ad26/protein preF RSV vaccine induced robust humoral and cellular immune responses in adults aged 18-59 years with or without chronic cardiac or pulmonary comorbidities, of similar magnitude to responses in older adults, allowing inference of efficacy and protection against RSV-associated respiratory disease in this population. www. CLINICALTRIALS: govNCT05070546.
引用
- Jastorff A, Gymnopoulou E, Salas J, et al. Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial. Vaccine. 2024. PMID: 39536455. doi:10.1016/j.vaccine.2024.126514
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。